O'Brien S - Search Results

1

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.

Zhao Y, Laird AD, Roberts KG, Yafawi R, Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien S, Jabbour E, Cassaday RD, Loyd MR, Olsen S, Neale G, Liu X, Vandendries E, Advani A, Mullighan CG. Zhao Y, et al. Blood Adv. 2024 Jun 25;8(12):3226-3236. doi: 10.1182/bloodadvances.2023012430. Blood Adv. 2024. PMID: 38607410 Free PMC article. Clinical Trial.

2

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).

Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, et al. Estey EH, et al. Blood. 1992 Feb 15;79(4):882-7. Blood. 1992. PMID: 1346577 Free article.

3

Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.

Kantarjian HM, Smith T, Estey E, Polyzos A, O'Brien S, Pierce S, Beran M, Feldman E, Keating MJ. Kantarjian HM, et al. Am J Med. 1992 Dec;93(6):599-604. doi: 10.1016/0002-9343(92)90191-d. Am J Med. 1992. PMID: 1466355

4

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.

Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Kantarjian HM, et al. J Clin Oncol. 1992 May;10(5):772-8. doi: 10.1200/JCO.1992.10.5.772. J Clin Oncol. 1992. PMID: 1569449

5

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

6

AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.

Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. Estey E, et al. Hematol Pathol. 1992;6(1):43-8. Hematol Pathol. 1992. PMID: 1601822

7

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

8

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Keating MJ, et al. J Clin Oncol. 1991 Jan;9(1):44-9. doi: 10.1200/JCO.1991.9.1.44. J Clin Oncol. 1991. PMID: 1702145 Clinical Trial.

9

Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.

Kantarjian HM, Estey EH, O'Brien S, Anaissie E, Beran M, Rios MB, Keating MJ, Gutterman J. Kantarjian HM, et al. Blood. 1992 Feb 15;79(4):876-81. Blood. 1992. PMID: 1737098 Free article.

10

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.

Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A. Kantarjian HM, et al. J Clin Oncol. 1992 Mar;10(3):398-405. doi: 10.1200/JCO.1992.10.3.398. J Clin Oncol. 1992. PMID: 1740679

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,110 results

Search Page

Filters